Childhood Acute Lymphoblastic Leukemia (ALL) requires specialized and immediate care, particularly when it’s the principal diagnosis leading to acute care inpatient settings. Understanding the treatment journey from diagnosis is crucial for families navigating this challenging time. For children over the age of one, a well-defined treatment path exists, spearheaded by expert teams in principal treatment centers.
Doctors at specialized children’s cancer centers, known as principal treatment centers (PTCs), meticulously plan your child’s treatment. This ensures your child benefits from the expertise of specialists in childhood ALL. While the PTC is central to care, treatment is often shared with a hospital closer to your home, referred to as a shared care hospital or pediatric oncology shared care unit (POSCU). This shared approach allows for some aspects of care, like blood tests and dressing changes, to potentially occur even at home, adding convenience and reducing hospital visits where possible.
Following a diagnosis of ALL, treatment commences swiftly. This urgency is due to the potential for ALL to rapidly cause severe health complications if left untreated. Pediatric cancer centers are equipped with multidisciplinary teams who specialize in childhood ALL and are adept at implementing the most effective treatment strategies. The advancements in treatment have dramatically improved outcomes, with over 90% of children with childhood ALL now achieving survival. Chemotherapy remains the cornerstone of ALL treatment.
Clinical Trials and Standard of Care
Clinical trials are integral to advancing ALL treatment, and for many children, participation in a clinical trial becomes a part of their care journey.
Chemotherapy is highly effective in treating children and young adults with ALL. Ongoing research emphasizes the importance of assessing the risk of leukemia recurrence (relapse) to tailor treatment intensity. This risk-stratified approach aims to minimize treatment for low-risk patients and intensify therapy for those at higher risk of relapse. International trials, such as the AllTogether-1 study, are frequently the framework within which children receive treatment, ensuring standardized and cutting-edge care.
Participation in a clinical trial is always voluntary. Children who do not participate still receive standard treatment protocols, which are known to be highly effective for the majority of children with ALL. The AllTogether-1 trial, a complex and long-term study, exemplifies the dedication to improving ALL treatment. For detailed insights into your child’s specific treatment plan within a trial or as standard care, direct consultation with your child’s medical team is essential.
Duration of Treatment and Inpatient Considerations
The total duration of ALL treatment extends for slightly over two years after the initial induction phase, which itself lasts approximately four weeks.
For a subset of children whose leukemia carries a very high risk of recurrence, treatment duration and type might differ. These children may require more intensive interventions like stem cell transplants or CAR-T cell therapy. While most of the treatment is delivered in an outpatient setting, the initial induction phase necessitates hospitalization. This inpatient stay, typically lasting a couple of weeks, allows for close monitoring and management as treatment begins. Throughout the treatment course, hospital stays may be necessary depending on how a child responds to therapy and the specific treatments administered.
Inpatient stays are specifically required for certain treatments later in the course, including stem cell transplants, CAR-T cell therapy, treatment with blinatumomab (a targeted drug), and high-dose methotrexate phases of chemotherapy.
Treatment Decisions: Factors and Considerations
A multidisciplinary team of specialists collaboratively develops a personalized treatment plan. This plan is carefully constructed based on several critical factors that help determine the most appropriate risk group and treatment strategy for your child, minimizing relapse risk.
These factors include:
-
Age: Children under 12 months or over 10 years old may be categorized differently.
-
Initial White Blood Cell Count: The level of white blood cells at diagnosis is a significant indicator.
-
Leukemia Cell Type: The specific type of leukemia cell involved influences treatment approach.
-
Central Nervous System Involvement: Presence of leukemia cells in the cerebrospinal fluid (brain and spinal cord fluid) is a crucial factor.
-
Genetic Abnormalities: Genetic changes within the leukemia cells, not inherited, are analyzed.
-
Predisposing Conditions: Conditions like Li-Fraumeni syndrome can influence treatment decisions, though Down syndrome is uniquely considered within current trial protocols.
-
Prior Cancer History: Previous cancer diagnoses are taken into account.
Chromosomal analysis of leukemia cells is performed to identify specific changes. One such change leads to Philadelphia positive ALL (Ph+ ALL). This subtype affects a small percentage of children with ALL and requires a modified treatment approach, typically including a targeted drug called Imatinib from the early stages of treatment. Your child’s doctor will provide a comprehensive explanation of the specific treatment plan if Ph+ ALL is diagnosed.
[Include Video Transcript Here – as provided in original article]
Monitoring Treatment Effectiveness: Measurable Residual Disease (MRD)
To assess the effectiveness of treatment, doctors regularly monitor your child’s response. A key method is the bone marrow aspirate, often performed around day 15 of treatment initiation and at subsequent intervals. Measurable Residual Disease (MRD) monitoring plays a vital role in gauging treatment response.
Measurable Residual Disease (MRD)
MRD testing is a highly sensitive technique that can detect minute levels of leukemia cells remaining in the bone marrow, even when standard remission tests suggest the leukemia is gone. Detecting MRD early in treatment is not necessarily indicative of treatment failure. Instead, it provides crucial information on how well your child is responding to the current treatment regimen.
Based on MRD results and other assessments, treatment adjustments may be made to optimize outcomes, ensuring your child receives the most effective therapy tailored to their response. Open communication with your medical team is encouraged. Asking questions and expressing concerns are vital aspects of navigating the treatment journey.
Phases of Treatment for Childhood ALL
ALL treatment is structured in phases or blocks. The specific phases and their intensity are determined by your child’s risk group. This risk stratification influences both the amount and strength of chemotherapy administered. Throughout each phase, your child is carefully monitored for side effects to ensure they are managed before proceeding to the next phase.
Clinical trials continuously explore refinements to treatment protocols, aiming to enhance efficacy and reduce long-term effects. These advancements may involve incorporating newer drugs or innovative treatment modalities into standard care. Should your child be eligible for any of these investigational approaches within a trial, the medical team will provide detailed information and discuss the options thoroughly.
Novel Therapies in Clinical Trials
Nelarabine: For children with high-risk T-cell ALL, nelarabine, a chemotherapy drug, may be incorporated into the treatment plan.
Blinatumomab: This drug might be used in specific situations, including children with Down syndrome (though this arm of the trial may not be actively recruiting), those experiencing severe chemotherapy side effects, or those with high-risk B cell precursor ALL (BCP ALL). Blinatumomab use is also contingent on MRD test results and local NHS trust availability.
Inotuzumab ozogamicin: This monoclonal antibody drug, targeting the CD22 protein on leukemia cells, is being investigated for potential benefit when added before maintenance therapy, aiming to further reduce relapse risk.
CAR T-cell therapy: For children with high-risk ALL who may not respond optimally to conventional chemotherapy, CAR T-cell therapy represents a promising innovative approach being explored in clinical trials. If CAR T-cell therapy is not available, alternative treatment options will be discussed.
Detailed Treatment Phases: Induction to Maintenance
Induction Treatment: The primary goal of induction is to achieve remission by eliminating as many leukemia cells as possible. This phase typically necessitates an initial hospital stay of approximately two weeks, allowing for close monitoring and immediate management of any complications. MRD testing is conducted at two points during induction to assess early treatment response.
Consolidation 1: This phase aims to further reduce any remaining leukemia cells and prevent spread to the brain and spinal cord. Consolidation 1 usually lasts about six weeks and is often administered in an outpatient or daycare setting.
Consolidation 2 and 3: These phases focus on eradicating any residual leukemia cells. High-dose methotrexate chemotherapy is commonly used, requiring brief hospital stays for each cycle. Consolidation 2 and 3 span approximately seven weeks. In some high-risk cases, these phases might be bypassed in favor of stem cell transplant or CAR T-cell therapy.
Delayed Intensification: Intensification employs strong chemotherapy drugs when minimal leukemia cells remain, aiming to further reduce the leukemia burden. The drugs used are often similar to those in induction and consolidation phases, primarily administered in an outpatient setting, though some inpatient stays may be required.
Maintenance: The longest phase, lasting two years post-induction, maintenance aims to prevent relapse. Treatment intensity is lower, typically outpatient chemotherapy, tailored to individual blood counts.
High Risk Blocks: These intensive chemotherapy blocks are introduced after consolidation 1 for children with high leukemia cell counts, high MRD, or T-cell ALL unresponsive to nelarabine. Three high-risk blocks are typically administered over about 10 weeks, potentially involving two rounds of high-risk treatment.
Stem Cell Transplant in Childhood ALL
Stem cell transplant is the most intensive treatment modality for ALL and may be recommended for specific high-risk cases when the benefits are deemed to outweigh the significant risks of side effects.
The transplant process involves high-dose chemotherapy and potentially radiotherapy to eliminate leukemia cells, followed by infusion of healthy stem cells to rebuild the bone marrow and immune system.
Supportive Care
Comprehensive supportive care is crucial throughout ALL treatment to manage side effects and prevent complications. This includes:
-
Anti-nausea medications: To control nausea and vomiting.
-
Antimicrobial medications: Antibiotics, antifungals, and antivirals to prevent and treat infections.
-
Blood product transfusions: Red blood cell and platelet transfusions to manage anemia and bleeding risks.
-
Tumor Lysis Syndrome Prevention: Medications to protect kidneys from tumor lysis syndrome.
-
Hydration: Intravenous fluids to maintain hydration.
-
Oral care: Mouthwashes and pain relief for mouth ulcers.
-
Menstrual suppression: Medication to stop periods if needed.
Management of Relapsed or Refractory ALL
In cases where leukemia is resistant to initial treatment (refractory) or returns after treatment (relapsed), further interventions are necessary. Treatment options may include:
- Chemotherapy: Different chemotherapy regimens.
- Stem cell transplant: If not previously performed.
- Targeted drugs: Blinatumomab or inotuzumab ozogamicin.
- Clinical trial participation: Access to novel therapies.
- CAR T-cell therapy: If not previously used.
- Radiotherapy or surgery: In specific cases, such as testicular relapse.
The consultant will discuss the most appropriate treatment strategies based on the specific circumstances of relapse or resistance.
Potential Side Effects of ALL Treatment
Treatment for ALL can cause immediate side effects during and shortly after therapy. These side effects vary depending on the specific treatments received and may include:
- Increased infection risk: Due to low white blood cell counts.
- Anemia: Breathlessness and paleness due to low red blood cell counts.
- Bleeding and bruising: Due to low platelet counts.
- Fatigue: Persistent tiredness.
- Mouth sores and gastrointestinal issues.
- Taste changes and appetite changes.
- Mobility and balance issues.
- Hair loss.
- Nausea and vomiting.
- Mood changes.
- Constipation.
- Blood clots in the head (rare), potentially causing headaches or seizures.
Hospitalization may be required to manage these side effects effectively. Treatment may be temporarily paused to allow for recovery. Open communication with the medical team is essential to address concerns and manage side effects throughout the treatment journey.
